Welcome to our dedicated page for Accuray Incorp news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorp stock.
Accuray Incorporated develops, sells, and supports radiation therapy systems used in cancer treatment and neuro-radiosurgery. Company news centers on product and service revenue, installation timing, gross margin factors, and non-GAAP operating measures, as well as updates tied to its CyberKnife and Radixact treatment platforms and the Accuray Stellar configuration.
Recurring developments also include commercial leadership changes, equity inducement awards, and strategic transformation actions involving organizational realignment, cost structure, outsourcing, engineering resources, and sales enablement. Accuray's updates frame the company as a medical technology issuer with capital equipment sales, service revenue, and global commercialization priorities.
Accuray (NASDAQ: ARAY) granted equity inducement awards under NASDAQ Listing Rule 5635(c)(4) to new executives Paul Miele, Chief Commercial Officer, and David Shin, Chief Legal Officer.
Miele received 650,000 RSUs and 650,000 PSUs; Shin received 375,000 RSUs and 375,000 PSUs, with time-based vesting starting in 2027 and PSU performance periods through fiscal 2028.
Accuray (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health announced a new 10-year Master Research Agreement focused on personalized cancer care using the Stellar adaptive radiation therapy platform.
The collaboration supports clinical research, education, training, and development of next-generation adaptive radiotherapy, building on UW’s role in inventing technology commercialized as Accuray’s TomoTherapy System.
Accuray (NASDAQ: ARAY) reported fiscal Q3 results for the period ended March 31, 2026. Total net revenue was $104.8M (down 7% YoY); product revenue $49.7M (down 13%); service revenue $55.1M (down 1%). GAAP net loss was $11.8M (diluted loss $0.09). Adjusted EBITDA was $3.8M. Order backlog was $356.2M. Company withdrew FY26 revenue and Adjusted EBITDA guidance due to Middle East geopolitical uncertainty. Transformation actions delivered ~$10M of cost and margin improvements to date.
Accuray (NASDAQ: ARAY) will report third quarter fiscal 2026 results for the period ended March 31, 2026, on May 6, 2026 with a conference call at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast and a one-week replay will be available via the Investor Relations website. Investor contact: Investor.relations@accuray.com.
Accuray (NASDAQ: ARAY) appointed Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will lead global commercial strategy across sales, marketing, pricing, market access, partnerships and launch excellence as the company pursues improved commercial execution and growth.
He joins with nearly two decades of global capital-medical device experience and a track record of reversing revenue declines and generating double-digit annual sales growth in prior roles.
Accuray (NASDAQ: ARAY) reported fiscal Q2 (ended Dec 31, 2025) results with $102.2M revenue, a 12% decline year-over-year, and a $13.8M net loss (diluted loss $0.11). Product revenue fell 26% to $45.0M while service revenue rose 4% to $57.2M.
Gross margin contracted to 23.5% from 36.1% and adjusted EBITDA was - $1.9M. The company recorded $6.1M of Q2 restructuring charges and expects ~$13M total FY2026 restructuring costs. Guidance was updated to $440–450M revenue and $22–25M adjusted EBITDA for FY2026.
Accuray (NASDAQ: ARAY) will report second quarter fiscal 2026 results for the period ended December 31, 2025, on February 4, 2026 at 1:30 p.m. PT / 4:30 p.m. ET. Management will host a conference call; live webcast and a one-week replay will be available from the company Investor Relations website. Dial-in numbers: 1-833-316-0563 (USA) and 1-412-317-5747 (international). Replay: 1-855-669-9658 (USA) and 1-412-317-0088 (international), conference ID 8587254. Webcast replay will remain posted until Accuray announces its third quarter fiscal 2026 results.
Investor contact: Aman Patel, CFA (ICR Healthcare). Media contact: Steve Monroe, VP Financial Planning & Analysis, Accuray.
Accuray (NASDAQ: ARAY) announced the first phase of a transformation plan on Dec 15, 2025 focused on organizational realignment, cost right-sizing, outsourcing, and sales enablement.
The company expects approximately $25 million of annualized operating profitability improvement, with about $12 million realized in fiscal 2026, and plans to implement nearly all initiatives by fiscal 2026 year-end. Actions include streamlining commercial structure, centralizing core functions, elevating global heads of service and product development to report to the CEO, reallocating engineering resources, and reducing global headcount by roughly 15%. Accuray expects restructuring charges of approximately $11 million across fiscal Q2–Q4 2026, most of which are expected to be cash charges.
Accuray (NASDAQ: ARAY) reported fiscal Q1 2026 results for the quarter ended Sept 30, 2025, and announced executive and transformation actions. Total net revenue was $93.9M (down 7% YoY). Product revenue was $37.2M (down 23% YoY) while service revenue was $56.8M (up 7% YoY). The company recorded $2.8M of restructuring charges and appointed Steve La Neve as CEO.
Profitability: gross profit was $26.5M (28.3% margin) vs $34.5M (33.9%) prior year; net loss was $21.7M or $0.18 per share vs loss $4.0M prior year. Adjusted EBITDA loss was $4.1M. Order backlog was $395.7M (≈16% lower YoY). Cash and equivalents were $63.9M. The company reaffirmed FY2026 guidance: revenue $471M–$485M and adjusted EBITDA $31M–$35M.
Accuray (NASDAQ: ARAY) announced inducement equity awards to new CEO Stephen La Neve effective October 31, 2025, granted outside the company’s existing equity plan under NASDAQ Rule 5635(c)(4).
The board approved 1,500,000 restricted stock units vesting 25% annually over four years and 1,500,000 performance-based restricted stock units (PSUs) tied to VWAP stock-price goals over an approximately six-year performance period ending September 30, 2031. PSUs are split into three tranches with specific price targets and dated vesting cutoffs in 2027, 2029, and 2031.